Clinical trials are an important way to improve treatment for people with cancer. While most are continuing during the COVID-19 pandemic, the period of time that clinical trials are available and recruiting may change quickly. If you would like to get involved in a clinical trial, speak to your treatment team or the health service where the clinical trial is being undertaken, to confirm it is open and appropriate for you. For cancer information and support, call Cancer Council's experienced cancer nurses on 13 11 20 Monday to Friday from 9am-5pm.

NCT04282018 : A Phase 1/2, Dose Escalation and Expansion Study of BGB-10188, a Phosphatidylinositol 3-Kinase Delta (PI3Kδ) Inhibitor, Combined With Zanubrutinib in Patients With Mature B-Cell Malignancies and Combined With Tislelizumab in Patients With Solid Tumors

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

One/TwoPhase One/Two

18+Age Over 18

Advanced CancersCancer LocationMulti-Cancer
Trial

Systemic therapy | Blood / Myeloma / Lymphoma,Female reproductive organs,Head and neck,Lung,Skin,Stomach and upper gastrointestinal tract,Urinary systemB-Cell Non Hodgkin Lymphoma,Cervix,Chronic Lymphocytic Leukaemia,Diffuse Large Cell Lymphoma,Endometrium,Follicular Lymphoma,Gastro-oesophageal junction ,Head and neck,Kidney,Liver,Lung,Lymphoma,Mantle Cell Lymphoma,Melanoma (Skin),Non-Small Cell Lung Cancer,Nose (nasopharynx),Oesophagus,Ovary,Renal cell carcinoma,Small Cell Lung Cancer,Squamous cell carcinoma ,Stomach

Trial Overview Read MoreRead more

This phase I/II trial is testing how safe and tolerable a new targeted cancer therapy is for the treatment of patients with mature B-cell blood cancer (when given in combination with the standard targeted therapy, zanubrutinib) or for patients with a type of advanced cancer (given in combination with the standard targeted therapy, tislelizumab).
 

This trial is treating patients with a type of b-cell blood cancer or advanced cancer.

This is a systemic therapy trial.

You may be able to join this trial if:

  • You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
  • Your cancer has spread to other parts of the body.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have had certain treatments, surgical procedures or drugs.
  • You have previously been treated (or are currently being treated) on a clinical trial.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Phase 1/2, Dose Escalation and Expansion Study of BGB-10188, a Phosphatidylinositol 3-Kinase Delta (PI3Kδ) Inhibitor, Combined With Zanubrutinib in Patients With Mature B-Cell Malignancies and Combined With Tislelizumab in Patients With Solid Tumors

Commercial Sponsor

BeiGene Australia Pty Ltd

Summary

Eligible patients will be assigned to receive BGB-10188: as monotherapy in participants with mature B-cell malignancies; in combination with zanubrutinib in participants with relapse/refractory follicular lymphoma (R/R FL), mantle cell lymphoma (MCL) or diffuse large B-cell lymphoma (DLBCL); and in combination with tislelizumab in participants with advanced solid tumors.

Recruiting Hospitals Read MoreRead more

Austin Health
Heidelberg
Ms Samantha Chakar
samantha.chakar@austin.org.au
03 9496 3088

Monash Health Haematology Research Unit
Clayton
Miss Jeanette Gamgee
jeanette.gamgee@monashhealth.org
03 9594 4044

Monash Health, Medical Oncology
Clayton
Early Phase Research Study Coordinator
earlyphase.oncresearch@monashhealth.org
0474 769 510

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next